Evidence map›Paper›PMID 41917262›Full record

ArticleThe EMBO journal2026

Mechanistic basis for selective Csm6-2 activation by cyclic penta-adenylate in a type III CRISPR-Cas system.

Ruyi Shi, Mengquan Yang, Yusong Liu, Haishan Gao, Zhonghui Lin

Abstract read
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruyi Shi *College of Chemistry, Fuzhou University, Fuzhou, China.ORCID http://orcid.org/0009-0004-3454-9568
Mengquan Yang *Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.ORCID http://orcid.org/0000-0001-5338-8318
Yusong LiuWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.ORCID http://orcid.org/0009-0000-1926-3503
Haishan GaoWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. gaohaishan@westlake.edu.cn.ORCID http://orcid.org/0000-0002-4954-8793
Zhonghui LinCollege of Chemistry, Fuzhou University, Fuzhou, China. zhonghui.lin@fzu.edu.cn.ORCID http://orcid.org/0000-0001-5797-7347

Funding

MOST | National Natural Science Foundation of China (NSFC) 32271258MOST | National Natural Science Foundation of China (NSFC) 32471255| Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation) 2024J02006
6 · The paper itself

Abstract

Type III CRISPR systems generate cyclic oligoadenylate (cOA, 3 to 6 AMPs) messengers upon detecting viral RNA, activating downstream effectors to defend against viral infection. Although cOA-activated effectors have been extensively characterized, the effectors specific to cA5-one of the most abundant cOA species produced during phage infection-have remained unexplored. Here, we report that the CRISPR ribonuclease Csm6 (Csm6-2) from Actinomyces procaprae selectively employs cA5 as its activator. Csm6-2 utilizes its HEPN domain, rather than the CARF domain, to mediate self-limiting cleavage of cOA activators. Cryo-EM structural analyses reveal that Csm6-2 functions as a homotetramer, and disruption of tetramer formation significantly reduces its ribonuclease activity. Although cA6 and cA5 bind Csm6-2 with comparable affinity, only cA5 induces CARF domain closure, stabilizes the tetramer, and remodels the active site in the HEPN domain. In contrast, the sixth AMP of cA6 imposes significant steric hindrance on CARF domain movement, preventing its closure and subsequent allosteric activation. These findings expand our understanding of the cOA signaling diversity and specific cOA recognition mechanisms in type III CRISPR immunity.

Indexed as

Adenine NucleotidesCRISPR-Associated ProteinsCRISPR-Cas SystemsOligoribonucleotidesRibonucleasesCryoelectron Microscopy2',5'-oligoadenylateAdenine NucleotidesCRISPR-Associated ProteinsOligoribonucleotidesRibonucleasesAllosteric ActivationCsm6Cyclic Penta-adenylateRibonucleaseType III CRISPR

Identifiers

PMID41917262
PMCPMC13187428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.